Authored by Cello Health BioConsulting, now part of Lumanity
“Why are investors and companies deploying hard earned resources to develop platforms comprised of novel cell types when first-mover T-cells have already demonstrated clinical and regulatory success?”
Perhaps more so than any other modality to date, cancer cell therapies have captured the imaginations and wherewithal of industry, investor, and oncologist communities alike. A fundamental but often vaguely understood component of emerging cell therapy platforms is the cell itself. In addition to peripherally-derived T-cells found in branded CAR-T products (e.g., Novartis’s Kymriah and Gilead’s Yescarta), additional cell-types are being developed as foundations of various novel cell-type platforms.
But why should investors and Pharma partners deploy scarce resources to develop novel cell-types? Can they unlock value and address shortcomings of first-mover CAR-T brands? Can they be delivered as truly ‘off-the-shelf’ products? Can they robustly and safely address solid tumors?
We’ve profiled Carisma Therapeutics, CoImmune, WindMIL Therapeutics in terms of their positioning within the cell therapy landscape based on our recent discussions with their executive management along with our own knowledgebase and in-house cell therapy databases that we curate for clients.
